Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses 1 , 2 and can function as …

During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor
subclones harboring unique resistance mechanisms in an individual patient 1 , 2 – 3 . Previous …

Personal neoantigen vaccines have been envisioned as an effective approach to induce,
amplify and diversify antitumor T cell responses. To define the long-term effects of such a …

ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2 -altered
ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor …

Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an
aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics …

PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma
(MM) with a 10% annual risk of progression. Various prognostic models exist for risk …

Driver mutations alter cells from normal to cancer through several evolutionary epochs:
premalignancy, early malignancy, subclonal diversification, metastasis and resistance to therapy. …

Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still
do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated …

Leukemic relapse remains a major barrier to successful allogeneic hematopoietic stem cell
transplantation (allo-HSCT) for aggressive hematologic malignancies. The basis for relapse …

Given a collection of rankings of a set of items, rank aggregation seeks to compute a ranking
that can serve as a single best representative of the collection. Rank aggregation is a well-…